

SECTION: Clinical ID NO.: CPI-9-809 PAGE: **1** of 3 ISSUE DATE: January 18, 2019 ISSUE.REVISION: 1.0 REVISION DATE: APPROVED BY: Quality Authority

Clinical Process Instruction Manual

Transplant Program – Suspected Donor Related Adverse Reaction Process Instruction

Policy:

Trillium Gift of Life Network (TGLN) as the source establishment for deceased organ and composite tissue donors, is required to report adverse reactions which have the possibility of being deceased donor related.

An adverse reaction is defined as an undesirable response in a tissue, organ, or composite tissue recipient, including transmission of disease or disease agent, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is life-threatening or results in death.

Only unexpected serious adverse reactions require Health Canada notification. As such, in cases of known risk (i.e., exceptional distribution), a serious adverse reaction does not need to be reported to Health Canada.

If the reaction is both serious and unexpected, TGLN will ensure it is appropriately reported to Health Canada (Canada Vigilance) and relevant establishments (transplant programs, tissue banks, organ procurement organizations).

Process:

- 1. Transplant program identifies a recipient who is experiencing an adverse event which may be donor related.
- 2. Transplant Program completes the *Transplant Program Suspected Donor Related Adverse Reaction Report* and submits it to TGLN's Quality Department. See Exhibit 1.
- 3. TGLN's Quality Director or designate reviews the form and follows-up with the Transplant Program within two business days of receiving the form to determine if the observed adverse reaction is reportable to Health Canada.
- 4. If it is determined that this is not a reportable adverse reaction (or that no adverse reaction has occurred), then TGLN's Quality Director informs the Transplant Program that the adverse reaction is not reportable and provides the rationale for this decision.



SECTION: Clinical ID NO.: CPI-9-809 PAGE: **2** of 3 ISSUE DATE: January 18, 2019 ISSUE.REVISION: 1.0 REVISION DATE: APPROVED BY: Quality Authority

Clinical Process Instruction Manual

Transplant Program – Suspected Donor Related Adverse Reaction Process Instruction

5. If it is determined that this is a reportable adverse reaction, TGLN carries out the activities described in *CPI-7-701 Unexpected Serious Adverse Reaction Process Instruction*.

Records:

Record Name	Form No. (if applicable)	Record Holder	Record Location	Record Retention Time (as a minimum)
Transplant Program – Suspected Donor Related Adverse Reaction Report	CSF-9-219	Quality Assurance Department	Quality Assurance Department	16 years

References:

• Safety of Human Cells, Tissues and Organs for Transplantation Regulations



SECTION: Clinical ID NO.: CPI-9-809 PAGE: **3** of 3 ISSUE DATE: January 18, 2019 ISSUE.REVISION: 1.0 REVISION DATE: APPROVED BY: Quality Authority

Clinical Process Instruction Manual

Transplant Program – Suspected Donor Related Adverse Reaction Process Instruction

Exhibit 1: Sample Transplant Program – Suspected Donor Related Adverse Reaction Report

Trillium	CSF-9-21 TRILLIUM GIFT OF LIFE NETWO
Gift of Life Network	483 Bay Street South Tower, 4* Floar Toroto, Omario MSC 5 Telephone (24/7): 1.877.363.8456 Facsimile: 1.886.567.01 CTO # 1000
TRANSPLANT PROGRAM – SUSPECTED	DONOR RELATED ADVERSE REACTION REPORT
Date:	
In the event an adverse reaction occurs in your transpla donor, please complete this form and return it to TGLN.	ant recipient, which possibly could be attributed to the deceased
being deceased donor related. By reporting these adve	ed to report adverse reactions which have the possibility of rse reactions to TGLN, we will be able to follow-up with other n has occurred in another recipient or prevent it from occurring if
	nse in a tissue, organ, or composite tissue recipient, including atient hospitalization or prolongation of existing hospitalization, , is life-threatening or results in death.
Step 1: Reporter Information	
Name of Transplant Program:	
Reporter's Name:	
Reporter's Phone Number/Email Address:	
Reporter's Qualification: Physician Nurse	Other (specify):
Step 2: Identification of a reportable suspected	Adverse reactions (check all that apply)
Cause/Prolonged hospitalization	□ Disabling/Incapacitating
□ Congenital anomaly in donor organ	□ Cancer (Type):
Other medially important condition (specify):	
Describe the reaction:	
Step 3: Recipient Information	
Recipient Name:	
TGLN Recipient Number:	
Step 4: Contact TGLN	
Please email this form to TGLN Quality at <u>Quality@gifte</u> the Quality Department within 2 business days.	oflife.on.ca. If there are any concerns, you will be contacted by